DK2074141T3 - Proteaseresistente insulinanaloger. - Google Patents

Proteaseresistente insulinanaloger. Download PDF

Info

Publication number
DK2074141T3
DK2074141T3 DK07820423.7T DK07820423T DK2074141T3 DK 2074141 T3 DK2074141 T3 DK 2074141T3 DK 07820423 T DK07820423 T DK 07820423T DK 2074141 T3 DK2074141 T3 DK 2074141T3
Authority
DK
Denmark
Prior art keywords
human insulin
desb30
insulin
desb30 human
glu
Prior art date
Application number
DK07820423.7T
Other languages
English (en)
Inventor
Peter Kresten Nielsen
Svend Ludvigsen
Ulla Ribel-Madsen
Frantisek Hubalek
Inger Lautrup-Larsen
Per Balschmidt
Per Nã¿Rgaard
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2074141(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK2074141T3 publication Critical patent/DK2074141T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Claims (37)

1. Insulinanalog, som sammenlignet med human insulin er stabiliseret mod nedbrydning, der skyldes enzymer fra gruppen, som består af pepsin, chymotrypsin, trypsin, insulin-degrading enzym (IDE), elastase, car-boxypepsidase, aminopeptidase og cathepsin D, hvorved aminosyren i position A14 er Glu, Asp eller His, og aminosyren i position B25 er His, hvilke aminosyrer i givet fald omfatter en eller flere yderligere mutationer, og hvorved T Vz er mindst 2 gange så lang som ved staminsulin.
2. Insulinanalog ifølge krav 1, hvorved T V2 sammenlignet med staminsulin er mindst 3 gange så lang.
3. Insulinanalog ifølge krav 1 eller krav 2, hvorved T Vz sammenlignet med staminsulin er mindst 4 gange så lang.
4. Insulinanalog ifølge et hvilket som helst af de foregående krav, hvorved T Vz sammenlignet med staminsulin er mindst 5 gange så lang.
5. Insulinanalog ifølge et hvilket som helst af de foregående krav, hvorved T V2 sammenlignet med staminsulin er mindst 10 gange så lang.
6. Insulinanalog ifølge et hvilket som helst af de foregående krav, og som ydermere omfatter én eller flere yderligere mutationer.
7. Insulinanalog ifølge et hvilket som helst af de foregående krav, og som omfatter en A-kæde-aminosyresekvens ifølge formel 1: XaaA<-2) -XaaA(-i)-XaaAo-Gly-lle-Val-Glu-Gln-Cys-XaaA8-Ser-lle-Cys-XaaAi2- XaaAi3-XaaAi4-XaaAi5-Leu-Glu-XaaAi8-Tyr-Cys-XaaA2i-Xaa22 Formel (1) (SEQ ID Nr. 1) Og en B-kæde-aminosyresekvens ifølge formel 2: XaaB(-2)-XaaB(-i)-XaaBo-XaaBi-XaaB2-XaaB3-XaaB4-His-Leu-Cys-Gly-Ser- XaaBio-Leu-Val-Glu-Ala-Leu-Val-Cys-Gly-Glu-Arg-XaaB24-XaaB24-XaaB25- XaaB26-XaaB27-XaaB28-XaaB29-XaaB3o-XaaB3i-XaaB32 Formel (2) (SEQ ID Nr. 2) hvorved XaaA(.2) mangler eller er Gly, XaaA(.i) mangler eller er Pro, XaaA0 mangler eller er Pro, XaaA8 er valgt uafhængigt blandt Thr og His, XaaA12 er valgt uafhængigt blandt Ser, Asp og Glu, XaaA13 er valgt uafhængigt blandt Leu, Thr, Asn, Asp, Gin, His, Lys, Gly, Arg, Pro, Ser og Glu, XaaA14 er valgt uafhængigt blandt Asp, His og Glu, XaaAi5 er valgt uafhængigt blandt Gin, Asp og Glu, XaaAis er valgt uafhængigt blandt Asn, Lys og Gin, XaaA2i er valgt uafhængigt blandt Asn og Gin, XaaA22 mangler eller er Lys, XaaB(-2> mangler eller er Gly, XaaB(-i> mangler eller er Pro, XaaBo mangler eller er Pro, XaaBi mangler eller er valgt uafhængigt blandt Phe og Glu, XaaB2 mangler eller er Val, XaaB3 mangler eller er valgt uafhængigt blandt Asn og Gin, XaaB4 er valgt uafhængigt blandt Gin og Glu, XaaB10 er valgt uafhængigt blandt His, Asp, Pro og Glu, XaaB16 er valgt uafhængigt blandt Tyr, Asp, Gin, His, Arg og Glu, XaaB24er valgt uafhængigt blandt Phe og His, XaaB25 er His, XaaB26 mangler eller er valgt uafhængigt blandt Tyr, His, Thr, Gly og Asp, XaaB27 mangler eller er valgt uafhængigt blandt Thr, Asn, Asp, Gin, His, Lys, Gly, Arg, Pro, Ser eller Glu, XaaB28 mangler eller er valgt uafhængigt blandt Pro, His, Gly og Asp, XaaB29 mangler eller er valgt uafhængigt blandt Lys og Gin, XaaB30 mangler eller er Thr, XaaB3i mangler eller er Leu, XaaB32 mangler eller er Glu, hvorved A-kæde-aminosyresekvensen og B-kæde-aminosyresekvensen er forbundet ved hjælp af disulfidbroer mellem cysteinerne i A-kædens position 7 og cysteinet i B-kædens position 7 samt mellem cysteinet i A-kædens position 20 og cysteinet i B-kædens position 19, og hvorved cysteinerne i A-kædens position 6 og 11 er forbundet ved hjælp af en disulfidbro.
8. Insulinanalog ifølge et hvilket som helst af de foregående krav, og som omfatter en A-kæde-aminosyresekvens med formlen 3: Gly-lle-Val-Glu-Cys-XaaA8-Ser-lle-Cys-XaaAi2-XaaAi3-XaaAi4- XaaAi5-Leu-Glu-XaaAi8-Tyr-Cys-XaaA2i Formel (3) (SEQ ID Nr. 3) og en B-kæde-aminosyresekvens i formel 4: XaaB1-Val-XaaB3-XaaB4-His-Leu-Cys-Gly-Ser-XaaBio-Leu-Val-Glu-Ala-Leu-XaaBi 6" Leu - Val - Cys- Glu - Arg - Gly-XaaB24· His-XaaB26"XaaB27_XaaB28_XaaB29· XaaB3o Formel (4) (SEQ) ID Nr. 4) hvorved XaaA8 er udvalgt uafhængigt blandt Thr og His, XaaAi2er udvalgt uafhængigt blandt Ser, Asp og Glu, XAi3 er udvalgt uafhængigt blandt Leu, Thr, Asn, Asp, Gin, His, Lys, Gly, Arg, Pro, Ser og Glu, XaaA14 er udvalgt uafhængigt blandt Asp, His og Glu, XaaA15 er udvalgt uafhængigt blandt Gin, Asp og Glu, XaaA18 er udvalgt uafhængigt blandt Asn, Lys og Gin, XaaA2i er udvalgt uafhængigt blandt Asn og Gin, XaaB1 er udvalgt uafhængigt blandt Phe og Glu, XaaB3 er udvalgt uafhængigt blandt Asn og Gin, XaaB4er udvalgt uafhængigt blandt Gin og Glu, XaaBioer udvalgt uafhængigt blandt His, Asp, Pro og Glu, XaaBie er udvalgt uafhængigt blandt Tyr, Asp, Gin, His, Arg og Glu, XaaB24 er udvalgt uafhængigt blandt Phe og His, XaaB26 mangler eller er udvalgt uafhængigt blandt Tyr, His, Thr, Gly og Asp, XaaB27 mangler eller er udvalgt uafhængigt blandt Thr, Asn, Asp, Gin, His, Lys, Gly, Arg, Pro, Ser og Glu, XaaB28 mangler eller er udvalgt uafhængigt blandt Pro, His, Gly og Asp, XaaB29 mangler eller er udvalgt uafhængigt blandt Lys og Gin, XaaB30 mangler eller er Thr, C-terminus kan i givet fald afledes som amid, hvorved A-kæde-aminosyresekvensen og B-kæde-aminosyresekvensen er forbundet ved hjælp af disulfidbroer mellem cysteinerne i A-kædens position 7 og cysteinet i B-kædens position 7 og mellem cysteinet i A-kædens position 20 og cysteinet i B-kædens position 19, og hvorved cysteinerne i A-kædens position 6 og position 11 er forbundet ved hjælp af en disulfidbro.
9. Insulinanalog ifølge krav 8, hvorved XaaA8er udvalgt uafhængigt af Thr og His, XaaAi2 er udvalgt uafhængigt af Ser og Glu, XaaAi3 er udvalgt blandt Leu, Thr, Asn, Asp, Gin, His, Lys, Gly, Arg, Pro, Ser og Glu, XaaAM er udvalgt uafhængigt blandt Asp, His og Glu, XaaA15 er udvalgt uafhængigt blandt Gin og Glu, XaaA18er udvalgt uafhængigt blandt Asn, Lys og Gin, XaaA2i er udvalgt uafhængigt blandt Asn og Gin, XaaB1 er udvalgt uafhængigt blandt Phe og Glu, XaaB3 er udvalgt uafhængigt blandt Asn og Gin, XaaB4er udvalgt uafhængigt blandt Gin og Glu, XaaB10 er udvalgt uafhængigt blandt His, Asp, Pro og Glu, XaaB16 er udvalgt uafhængigt blandt Tyr, Asp, Gin, His, Arg og Glu, XaaB24 er udvalgt uafhængigt blandt Phe og His, XaaB26 er udvalgt uafhængigt blandt Tyr, Thr, Gly og Asp, XaaB27 er udvalgt uafhængigt blandt Thr, Asn, Asp, Gin, His, Lys, Gly, Arg og Glu, XaaB28 er udvalgt uafhængigt blandt Pro, Gly og Asp, XaaB29 er udvalgt uafhængigt blandt Lys og Gin, XaaB3o mangler eller er Thr, C-terminus i givet fald kan afledes som Amid, hvorved A-kæde-aminosyresekvensen og B-kæde-aminosyresekvensen er forbundet ved hjælp af disulfidbroer mellem cysteinerne i A-kædens position 7 og cysteinet i B-kædens position 7 og mellem cysteinet i A-kædens position 20 og cysteinet i B-kædens position 19, og hvorved cysteinerne i A-kædens position 6 og position 11 er forbundet ved hjælp af en disu If idbro.
10. Insulinanalog ifølge et hvilket som helst af kravene 7 til 9, hvorved C-terminus er afledt som amid.
11. Insulinanalog ifølge et hvilket som helst af kravene 7 til 10, hvorved den N-terminale A-kæde-aminosyresekvens ved hjælp af en 3-7 aminosyre-omfattende am inosyresekvens er forbundet med den C-terminale B-kæde-aminosyresekvens, idet der dannes et én-kædet insulinmolekyle.
12. Insulinanalog ifølge et hvilket som helst af kravene 7 til 11, hvorved B-kædens N-terminus er forlænget med 1 til 10 aminosyrer.
13. Insulinanalog ifølge et hvilket som helst af de foregående krav, hvorved der opnås en i forhold til staminsulin forhøjet opløselighed.
14. Insulinanalog ifølge et hvilket som helst af de foregående krav, hvorved aminosyrerne i position A14 er Glu, Asp eller His, aminosyren i position B25 er His, og aminosyren i position B30 er slettet.
15. Insulinanalog ifølge et hvilket som helst af kravene 1 til 13, hvorved aminosyren i position A14 er Glu, Asp eller His, og aminosyren i position B25 er His.
16. Insulinanalog ifølge et hvilket som helst af de foregående krav, hvorved den yderligere mutation er desB30.
17. Insulinanalog ifølge et hvilket som helst af de foregående krav, hvorved A14 er Glu.
18. Insulinanalog ifølge et hvilket som helst af de foregående krav, og som sammenlignet med staminsulin omfatter mindre end 8 modifikationer (substitutioner, udeladelser, tilføjelser).
19. Insulinanalog ifølge et hvilket som helst af de foregående krav, og som sammenlignet med staminsulin omfatter mindre end 7 modifikationer (substitutioner, udeladelser, tilføjelser).
20. Insulinanalog ifølge et hvilket som helst af de foregående krav, og som sammenlignet med staminsulin omfatter mindre end 6 modifikationer (substitutioner, udeladelser, tilføjelser).
21. Insulinanalog ifølge et hvilket som helst af de foregående krav, og som sammenlignet med staminsulin omfatter mindre end 5 modifikationer (substitutioner, udeladelser, tilføjelser).
22. Insulinanalog ifølge et hvilket som helst af de foregående krav, og som sammenlignet med staminsulin omfatter mindre end 4 modifikationer (substitutioner, udeladelser, tilføjelser).
23. Insulinanalog ifølge et hvilket som helst af de foregående krav, og som sammenlignet med staminsulin omfatter mindre end 3 modifikationer (substitutioner, udeladelser, tilføjelser).
24. Insulinanalog ifølge krav 1, udvalgt fra gruppen, der består af: A14E, B25H, desB30-human insulin, A14H, B25H, desB30-human insulin, A14E, B1 E, B25H, desB30-human insulin, A14E, B16E, B25H, des B30-human insulin, A14E, B25H, B28D, des B30-human insulin, A14E, B25H, B27E, desB30-human insulin, A14E, B1 E, B25H, B27E, desB30-human insulin, A14E, B1 E, B16E, B25H, B27E, desB30-human insulin, A8H, A14E, B25H, desB30-human insulin, A8H, A14E, B25H, B27E, des B30-human insulin, A8H, A14E, B1 E, B25H, desB30-human insulin, A8H, A14E, B1E, B25H, B27E, desB30-human insulin, A8H, A14E, B1E, B16E, B25H, B27E, desB30-human insulin, A8H, A14E, B16E, B25H, desB30-human insulin, A14E, B25H, B26D, desB30-human insulin, A14D, B25H, desB30-human insulin, A(-1)P, Α(0)Ρ, A14E, B25H, desB30-human insulin, A14E, B(-1 )P, B(0)P, B25H, desB30-human insulin, A(-1)P, Α(0)Ρ, A14E, B(-1)P, Β(0)Ρ, B25H, des B30-human insulin, A14E, B25H, B30T, B32E-human insulin, A14E, B25H-human insulin, A14E, B16H, B25H, desB30-human insulin, A14E, B10P, B25H, desB30- human insulin, A14E, B10E, B25H, desB30-human insulin, A14E, B4E, B25H, desB30-human insulin, A14H, B16H, B25H, desB30-human insulin, A14H, B10E, B25H, desB30-human insulin, A14E, B25H, desB27, desB28, desB29, desB30-human insulin, A13H, A14E, B10E, B25H, desB30-human insulin, A13H, A14E, B25H, desB30-human insulin, A14E, A18Q, B25H, desB30-human insulin, A14E, B24H, B25H, desB30-human insulin, A8H, A14E, B10D, B25H, B26G, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, des B26, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, B26G, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, B26G, B27G, B28G, desB30-human insulin, A14E, A18Q, A21Q, B3Q, B25H, desB30-human insulin, A14E, A18Q, A21Q, B3Q, B25H, B27E, desB30-human insulin, A14E, A18Q, B3Q, B25H, desB30-human insulin, A13H, A14E, B1 E, B25H, desB30-human insulin, A13N, A14E, B25H, desB30-human insulin, A13N, A14E, B1 E, B25H, desB30-human insulin, A(-2)G, A(-1)P, Α(0)Ρ, A14E, B25H, desB30-human insulin, A14E, B(-2)G, B(-1)P, B(0)P, B25(H), desB30-human insulin, A(-2)G, A(-1)P, Α(0)Ρ, A14E, B(-2)G, B(-1)P, Β(0)Ρ, B25H, desB30-human insulin, A14E, B25H, B27R, B28D, B29K, desB30-human insulin, A14E, B25H, B26T, B27R, B28D, B29K, desB30-human insulin, A14E, A18K, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, A22K, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, A22K, B25H, desB30-human insulin, A14E, desB1, desB2, desB3, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, desB1, desB2, desB3, B16H, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, B27R, desB30-human insulin, A14E, B25H, B27H, desB30-human insulin, A14E, B25H, B27R, desB28-B30-human insulin, A14E, B25H, B27H, desB28-B30-human insulin, A14E, B25H, B27E, desB28-B30-human insulin, A14E, B25H, B27K, desB28-B30-human insulin, A13E, A14E, B25H, desB30-human insulin, A12E, A14E, B25H, desB30-human insulin, A15E, A14E, B25H, desB30-human insulin, A14E, B25H, desB27, desB30-human insulin, A14E, B25H, B26D, B27E, desB30-human insulin, EEAEAEAPK-B(1 - 29)-B25H-AAK-A(1 - 21 )-A14E-human insulin, EEAEPK-B(1 -29)-B25H-DGK-A(1 - 21 )-A14E-human insulin, B(1 -29)-B25H-AAK-A(1 -21 )-A14E-human insulin, B(1 -29)-B1 E, B25H-AAK-A(1 - 21 )-A14E-human insulin, B( 1 -29)-B25H, B27E-AAK-A(1-21 )-A8H, A14E-human-insulin, B( 1 -29)-B1 E, B25H, B27E-AAK-A( 1 -21), A8H, A14E-human-insulin, EEAEAEAPK-B(1-29)-B16E, B25H-AAK-A( 1 - 21 )-A8H, A14E-human- insulin, B(1 -29)-B25H, B29Q-TGLGGGQ-A(1-21 )-A14E-human insulin, B(1-29)-B16E, B25H, B29Q-TGLGGGQ-A( 1 -21 )-A14E-human insulin, B(1 -29)-B25H, B29Q-TGLGGGQ-A( 1 -21 )-A8H, A14E-human insulin, A14E, B25H, B27N, desB30-human insulin, A14E, B25H, B27D, desB30-human insulin, A14E, B25H, B27Q, desB30-humaninsulin, A14E, B25H, B27G, desB30-human insulin, A14E, B25H, B27K, desB30-human insulin A14E, B25H, B27P, desB30-human insulin, A14E, B25H, B27S, desB30-human insulin, A14E, B25H, B27T, des-B30-human insulin, A13R, A14E, B25H, desB30-human insulin, A13N, A14E, B25H, desB30-human insulin, A13D, A14E, B25H, desB30-human insulin, A13Q, A14E, B25H, desB30-human insulin, A13G, A14E, B25H, desB30-human insulin, A13H, A14E, B25H, desB30-human insulin, A13K, A14E, B25H, desB30-human insulin, A13P, A14E, B25H, desB30-human insulin, A13S, A14E, B25H, desB30-human insulin, A13T, A14E, B25H, desB30-human insulin, A14E, B16R, B25H, desB30-human insulin, A14E, B16D, B25H, desB30-human insulin, A14E, B1 6Q, B25H, desB30-human insulin, A14E, B16E, B25H, desB30-human insulin og A8H, A14E, B10E, B25H, desB30-human insulin.
25. Insulinanalog ifølge krav 1, udvalgt fra gruppen, som består af: A14E, B25H, desB30-human insulin, A14H, B25H, desB30-human insulin, A14E, B1 E, B25H, desB30-human insulin, A14E, B16E, B25H, desB30-human insulin, A14E, B25H, B28D, desB30-human insulin, A14E, B25H, B27E, desB30-human insulin, A14E, B1 E, B25H, B27E, desB30-human insulin, A14E, B1E, B16E, B25H, B27E, desB30-human insulin, A8H, A14E, B25H, desB30-human insulin, A8H, A14E, B25H, B27E, desB30-human insulin, A8H, A14E, B1 E, B25H, desB30-human insulin, A8H, A14E, B1E, B25H, B27E, desB30-human insulin, A8H, A14E, B1E, B16E, B25H, B27H, B27E, desB30-human insulin, A8H, A14E, B16E, B25H, desB30-human insulin, A14E, B25H, B26D, desB30-human insulin, A14D, B25H, desB30-human insulin, A(-1)P, Α(0)Ρ, A14E, B25H, desB30-human insulin, A14E, B( -1)P, B(0)P, B25H, desB30-human insulin, A(-1)P, Α(0)Ρ, A14E, B(-1)P, Β(0)Ρ, B25H, desB30-human insulin, A14E, B25H, B30T, B31L, B32E-human insulin, A14E, B25H-human insulin, A14E, B16H, B25H, desB30-human insulin, A14E, B10P, B25H, desB30-human insulin, A14E, B10E, B25H, desB30-human insulin, A14E, B4E, B25H, desB30-human insulin, A14H, B16H, B25H, desB30-human insulin, A14H, B10E, B25H, desB30-hum an insulin, A14E, B25H, desB27, desB28, desB29, desB30-human insulin, A13H, A14E, B10E, B25H, desB30-human insulin, A13H, A14E, B25H, desB30-human insulin, A14E, A18Q, B3Q, B25H, desB30-human insulin, A14E, B24H, B25H, desB30-human insulin, A8H, A14E, B10D, B25H, B26G, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, desB26, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, B26G, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, B26G, B27G, B28G, desB30-human insulin, A14E, A18Q, A21Q, B3Q, B25H, desB30-human insulin, A14E, A18Q, A21Q, B3Q, B25H, B27E, desB30-human insulin, A14E, A18Q, B3Q, B25H, desB30-human insulin, A13H, A14E, B1 E, B25H, desB30-human insulin; A13N, A14E, B25H, desB30-human insulin, A13N, A14E, B1 E, B25H, desB30-human insulin, A(-2)G, A(-1)P, Α(0)Ρ, A14E, B25H, desB30-human insulin, A14E, B(-2)G, B(-1)P, Β(0)Ρ, B25H, desB30-human insulin, A(-2)G, A(-1 )P, A(0)P, A14E, B(-2)G, B(-1)P, Β(0)Ρ, B25H, desB30-human insulin, A14E, B25H, B27R, B28D, B29K, desB30-human insulin, A14E, B25H, B26T, B27R, B28D, B29K, desB30-human insulin, A14E, A18K, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, A22K, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, A22K, B25H, desB30-human insulin, A14E, desB1, desB2, desB3, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, desB1, desB2, desB3, B16H, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, B27R, desB30-human insulin, A14E, B25H, B27H, desB30-human insulin, A14E, B25H, B27R, desB28-B30-human insulin, A14E, B25H, B27H, desB28-B30-human insulin, A14E, B25H, B27E, desB28-B30-human insulin, A14E, B25H, B27K, desB28-B30-human insulin, A14E, A18Q, B3Q, B25H, desB30-human insulin, A13E, A14E, B25H, desB30-human insulin, A12E, A14E, B25H, desB30-human insulin, A15E, A14E, B25H, desB30-human insulin, A14E, B25H, desB27, desB30-human insulin, A14E, B25H, B26D, B27E, desB30-human insulin, A14E, B25H, B27N, desB30-human insulin, A14E, B25H, B27D, desB30-human insulin, A14E, B25H, B27Q, desB30-human insulin, A14E, B25H, B27G, desB30-human insulin, A14E, B25H, B27K, desB30-human insulin, A14E, B25H, B27P, desB30-human insulin, A14E, B25H, B27S, desB30-human insulin, A14E, B25H, B27T, desB30-human insulin, A13R, A14E, B25H, desB30-human insulin, A13N, A14E, B25H, desB30-human insulin, A13D, A14E, B25H, desB30-human insulin, A13Q, A14E, B25H, desB30-human insulin, A13E, A14E, B25H, desB30-human insulin, A13G, A14E, B25H, desB30-human insulin, A13H, A14E, B25H, desB30-human insulin, A13K, A14E, B25H, desB30-human insulin, A13P, A14E, B25H, desB30-human insulin, A13S, A14E, B25H, desB30-human insulin, A13T, A14E, B25H, desB30-human insulin, A14E, B16R, B25H, desB30-human insulin, A14E, B16D, B25H, desB30-human insulin, A14E, B16Q, B25H, desB30-human insulin, A14E, B16E, B25H, desB30-human insulin og A8H, A14E, B10E, B25H, desB30-human insulin.
26. Insulinanalog ifølge krav 1, udvalgt fra gruppen, som består af: A14E, B25H, desB30-human insulin, A14E, B1 E, B25H, desB30-human insulin, A14E, B16E, B25H, desB30-human insulin, A14E, B25H, B28D, desB30-human insulin, A14E, B25H, B27E, desB30-human insulin, A14E, B1 E, B25H, B27E, desB30-human insulin, A14E, B1E, B16E, B25H, B27E, desB30-human insulin, A8H, A14E, B25H, desB30-human insulin, A8H, A14E, B25H, B27E, desB30-human insulin, A8H, A14E, B1 E, B25H, desB30-human insulin, A8H, A14E, B1E, B25H, B27E, desB30-human insulin, A8H, A14E, B1E, B16E, B25H, B27E, desB30-human insulin, A8H, A14E, B16E, B25H, desB30-human insulin, A14E, B25H, B26D, desB30-human insulin, A(-1)P, Α(0)Ρ, A14E, B25H, desB30-human insulin, A14E, B(-1)P, Β(0)Ρ, B25H, desB30-human insulin, A(-1)P, Α(0)Ρ, A14E, B(-1)P, b(0)P, B25H, desB30-human insulin. A14E, B25H, B30T, B31L, B32E-human insulin, A14E, B25H-human insulin, A14E, B16H, B25H, desB30-human insulin, A14E, B10P, B25H, desB30-human insulin, A14E, B10E, B25H, desB30-human insulin, A14E, B4E, B25H, desB30-human insulin, A14E, B25H, desB27, desB28, desB29, desB30-human insulin, A13H, A14E, B10E, B25H, desB30-human insulin, A13H, A14E, B25H, desB30-human insulin, A14E, A18Q, B3Q, B25H, desB30-human insulin, A14E, B24H, B25H, desB30-human insulin, A8H, A14E, B10D, B25H, B26G, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, desB26, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, B26G, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, B26G, B27G, B28G, desB30-human insulin, A14E, B25H, desB26, desB27, desB28, desB29, desB30-human insulin, A14E, A18Q, A21Q, B3Q, B25H, desB30-human insulin, A14E, A18Q, A21Q, B3Q, B25H, B27E, desB30-human insulin, A14E, A18Q, B3Q, B25H, desB30-human insulin, A13H, A14E, B1 E, B25H, desB30-human insulin, A13N, A14E, B25H, desB30-human insulin, A13N, A14E, B1 E, B25H, desB30-human insulin, A(-2)G, A(-1)P, A(0)P, A14E, B25H, desB30-human insulin, A14E, B(-2)G, B(-1)P, Β(0)Ρ, B25H, desB30-human insulin, A(-2)G, A(-1)P, Α(0)Ρ, A14E, B(-2)G, B(-1)P, Β(0)Ρ, B25H, desB30-human insulin, A14E, B25H, B27R, B28D, B29K, desB30-human insulin, A14E, B25H, B26T, B27R, B28D, B29K, desB30-human insulin, A14E, A18K, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, A22K, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, A22K, B25H, desB30-human insulin, A14E, desB1, desB2, desB3, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, desB1, desB2, desB3, B16H, B25H, desB27, desB28, desB29, desB30-human insulin, A14E, B25H, B27R, desB30-human insulin, A14E, B25H, B27H, desB30-human insulin, A14E, B25H, B27R, desB28-B30-human insulin, A14E, B25H, B27H, desB28-B30-human insulin, A14E, B25H, B27E, DesB28-B30-human insulin, A14E, B25H, B27K, desB28-B30-human insulin, A14E, A18Q, B3Q, B25H, desB30-human insulin, A13E, A14E, B25H, desB30-human insulin, A12E, A14E, B25H, desB30-human insulin, A15E, A14E, B25H, desB30-human insulin, A14E, B25H, desB27, desB30-human insulin, A14E, B25H, B26D, B27E, desB30-human insulin, A14E, B25H, B27N, desB30-human insulin, A14E, B25H, B27D, desB30-human insulin, A14E, B25H, B27Q, desB30-human insulin, A14E, B25H, B27G, desB30-human insulin, A14E, B25H, B27K, desB30-human insulin, A14E, B25H, B27P, desB30-human insulin, A14E, B25H, B27S, desB30-human insulin, A14E, B25H, B27T, desB30-human insulin, A13R, A14E, B25H, desB30-human insulin, A13N, A14E, B25H, desB30-human insulin, A13D, A14E, B25H, desB30-human insulin, A13Q, A14E, B25H, desB30-human insulin, A13G, A14E, B25H, desB30-human insulin, A13H, A14E, B25H, desB30-human insulin, A13K, A14E, B25H, desB30-human insulin, A13P, A14E, B25H, desB30-human insulin, A13S, A14E, B25H, desB30-human insulin, A13T, A14E, B25H, desB30-human insulin, A14E, B16R, B25H, desB30-human insulin, A14E, B16D, B25H, desB30-human insulin, A14E, B1 6Q, B25H, desB30-human insulin, A14E, B16E, B25H, desB30-human insulin og A8H, A14E, B10E, B25H, desB30-human insulin.
27. Insulinanalog ifølge krav 1, udvalgt fra gruppen, som består af: A14E, B25H, desB30-human insulin, A14E, B1 E, B25H, desB30-human insulin, A14E, B16E, B25H, desB30-human insulin, A14E, B25H, B28D, desB30-human insulin, A14E, B25H, B27E, desB30-human insulin, A8H, A14E, B25H, desB30-human insulin, A14E, B25H, B26D, desB30-human insulin, A14E, B25H-human insulin, A14E, B16H, B25H, desB30-human insulin, A14E, B10P, B25H, desB30-human insulin, A14E, B10E, B25H, desB30-human insulin, A14E, B4E, B25H, desB30-human insulin, A13H, A14E, B25H, desB30-human insulin, A14E, B24H, B25H, desB30-human insulin, A13N, A14E, B25H, desB30-human insulin, A14E, A22K, B25H, desB30-human insulin, A14E, B25H, B27R, desB30-human insulin, A14E, B25H, B27H, desB30-human insulin, A13E, A14E, B25H, desB30-human insulin, A12E, A14E, B25H, desB30-human insulin, A15E, A14E, B25H, desB30-human insulin, A14E, B25H, desB27, desB30-human insulin, A14E, B25H, B27N, desB30-human insulin, A14E, B25H, B27D, desB30-human insulin, A14E, B25H, B27Q, desB30-human insulin, A14E, B25H, B27G, desB30-human insulin, A14E, B25H, B27H, desB30-human insulin, A14E, B25H, B27K, desB30-human insulin, A14E, B25H, B27P, desB30-human insulin, A14E, B25H, B27S, desB30-human insulin, A14E, B25H, B27T, desB30-human insulin, A13R, A14E, B25H, desB30-human insulin, A13N, A14E, B25H, desB30-human insulin, A13D, A14E, B25H, desB30-human insulin, A13Q, A14E, B25H, desB30-human insulin, A13G, A14E, B25H, desB30-human insulin, A13H, A14E, B25H, desB30-human insulin, A13K, A14E, B25H, desB30-human insulin, A13P, A14E, B25H, desB30-human insulin, A13S, A14E, B25H, desB30-human insulin, A13T, A14E, B25H, desB30-human insulin, A14E, B16R, B25H, desB30-human insulin, A14E, B16D, B25H, desB30-human insulin, A14E, B1 6Q, B25H, desB30-human insulin, A14E, B16E, B25H, desB30-human insulin, A14E, B25H, desB30-human insulin.
28. Insulinanalog ifølge krav 1, udvalgt fra gruppen, som består af: A14E, B25H, desB27, desB28, desB29, desB30-human insulin, A8H, A14E, B25H, B27E, desB30-human insulin, EEAEAEAPK-B(1 -29)-B25H-AAK-A(1 -21 )-A14E-human insulin, A8H, A14E, B1E, B25H, B27E, desB30-human insulin, A14E, B25H, B28D, desB30-human insulin, A14E, B25H, B26D, desB30-human insulin, A14E, B25H, B27E, desB30-human insulin, A8H, A14E, B25H, desB30-human insulin, A8H, A14E, B10E, B25H, desB30-human insulin, A14E, B25H, desB30-human insulin, A14E, B1 E, B25H, B27E, desB30-human insulin, A8H, A14E, B1 E, B25H, desB30-human insulin, A8H, A14E, B1E, B16E, B25H, B27E, desB30-human insulin, A14D, B25H, desB30-human insulin, A14E, B1 E, B16E, B25H, B27E, desB30-human insulin, A14E, B1 E, B25H, desB30-human insulin, A14H, B25H, desB30-human insulin, A14E, B25H-human insulin, A8H, A14E, B16E, B25H, desB30-human insulin, og A14E, B16E, B25H, desB30-human insulin.
29. Insulinanalog ifølge krav 1, hvorved det drejer sig om A14E, B25H, desB30-insulin.
30. Insulinanalog ifølge krav 1, hvorved det drejer sig om A14E, B16E, B25H, desB30-human insulin.
31. Insulinanalog ifølge krav 1, hvorved det drejer sig om A14E, B16H, B25H, desB30-human insulin.
32. Insulinanalog ifølge krav 1, hvorved det drejer sig om A14E, B25H, desB30-human insulin.
33. Farmaceutisk sammensætning, omfattende en biologisk virksom mængde af insulinanalogen ifølge et hvilket som helst af de foregående krav, samt en farmaceutisk acceptabel bærer.
34. Insulinanalog ifølge et hvilket som helst af kravene 1 til 32 med henblik på anvendelse som farmaceutikum ved behandlingen eller forebyggelsen af hyperglæmi, type-2-diabetes, glukose-intolerans og type-1 -diabetes.
35. Insulinanalog ifølge et hvilket som helst af kravene 1 til 32 med henblik på anvendelse som farmaceutikum ved forsinkelse eller forhindring af sygdommens fremadskriden ved type-2-diabetes.
36. Nukleinsyresekvens, der koder for en insulinanalog ifølge et hvilket som helst af kravene 1 til 32.
37. Fremgangsmåde til fremstilling af en farmaceutisk sammensætning ifølge krav 33, hvorved der sker blanding af en insulinanalog ifølge et hvilket som helst af kravene 1 til 32 med farmaceutisk acceptable stoffer og/eller excipienter.
DK07820423.7T 2006-09-22 2007-09-20 Proteaseresistente insulinanaloger. DK2074141T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121113 2006-09-22
PCT/EP2007/059990 WO2008034881A1 (en) 2006-09-22 2007-09-20 Protease resistant insulin analogues

Publications (1)

Publication Number Publication Date
DK2074141T3 true DK2074141T3 (da) 2016-11-28

Family

ID=38754488

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07820423.7T DK2074141T3 (da) 2006-09-22 2007-09-20 Proteaseresistente insulinanaloger.

Country Status (20)

Country Link
US (1) US9018161B2 (da)
EP (2) EP2404934A1 (da)
JP (2) JP5864834B2 (da)
KR (2) KR101699370B1 (da)
CN (1) CN101541830A (da)
AU (1) AU2007298919C1 (da)
BR (1) BRPI0717098B8 (da)
CA (1) CA2663074A1 (da)
DK (1) DK2074141T3 (da)
ES (1) ES2601839T3 (da)
HU (1) HUE029512T2 (da)
IL (1) IL197609A (da)
MX (1) MX2009002999A (da)
NO (1) NO20091563L (da)
PL (1) PL2074141T3 (da)
PT (1) PT2074141T (da)
RU (1) RU2524150C2 (da)
TW (1) TW200829600A (da)
WO (1) WO2008034881A1 (da)
ZA (1) ZA200901838B (da)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
DK2074141T3 (da) 2006-09-22 2016-11-28 Novo Nordisk As Proteaseresistente insulinanaloger.
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
AU2008257505B2 (en) 2007-06-01 2013-05-16 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
WO2009112583A2 (en) * 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
CN102037008B (zh) * 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
WO2009133099A2 (en) * 2008-04-28 2009-11-05 Novo Nordisk A/S Insulin precursors for diabetes treatment
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP2012511506A (ja) * 2008-12-09 2012-05-24 ノヴォ・ノルディスク・アー／エス 新規インスリンアナログ
AU2010264636B2 (en) 2009-06-26 2013-06-27 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
WO2011000823A1 (en) 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
US20120232002A1 (en) * 2009-07-06 2012-09-13 Sanofi-Aventis Deutschland Gmbh Slow-acting insulin preparations
US20120196800A1 (en) 2009-09-16 2012-08-02 Novo Nordisk A/S Stable non-aqueous liquid pharmaceutical compositions comprising an insulin
EP2496213B1 (en) 2009-11-02 2015-08-12 Novo Nordisk A/S Pharmaceutical solution of non covalently bound albumin and acylated insulin
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
CA2786953A1 (en) 2010-01-12 2011-07-21 Florian Anders Foeger Pharmaceutical compositions for oral administration of insulin peptides
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
RU2598273C2 (ru) * 2010-06-23 2016-09-20 Ново Нордиск А/С Производные инсулина, содержащие дополнительные дисульфидные связи
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
CN102933599A (zh) * 2010-06-23 2013-02-13 诺沃—诺迪斯克有限公司 包含额外的二硫键的人胰岛素
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
JP2013545782A (ja) 2010-12-14 2013-12-26 ノヴォ ノルディスク アー／エス 長時間作用型インスリンと組み合わせた速効型インスリン
MX2013006174A (es) 2010-12-14 2013-07-15 Novo Nordisk As Preparacion que comprende insulina, nicotinamida y un aminoacido.
WO2012140155A1 (en) 2011-04-14 2012-10-18 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103596584B (zh) 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2768520A4 (en) * 2011-10-18 2015-07-15 AmideBio LLC CHEMICAL AND THERMODYNAMIC STABLE INSULIN ANALOGUE AND IMPROVED PROCESS FOR THEIR PREPARATION
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
WO2014060447A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated d-amino acids for oral peptide delivery
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
JP6364067B2 (ja) 2013-04-05 2018-07-25 ノボ・ノルデイスク・エー／エス 薬剤送達装置の投与記録装置
EP2986315A4 (en) 2013-04-17 2017-03-01 AmideBio LLC Chemically and thermodynamically stable insulin analogues and improved methods for their production
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
US20180000742A1 (en) * 2015-01-29 2018-01-04 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CR20190096A (es) 2016-07-22 2019-09-16 Walter & Eliza Hall Inst Medical Res Análogos de insulina
RU2764197C1 (ru) * 2016-09-23 2022-01-14 Ханми Фарм. Ко., Лтд. Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
MA46568A (fr) * 2016-10-24 2019-08-28 Novo Nordisk As Dosage biologique de formulations d'insuline
MA46780A (fr) 2016-11-07 2019-09-11 Novo Nordisk As Esters à dchbs actif de composés peg et leur utilisation
MX389336B (es) 2016-11-15 2025-03-20 Klaria Pharma Holding Ab Formulacion farmaceutica.
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
AR111341A1 (es) * 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
CN110505885A (zh) 2017-04-05 2019-11-26 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
CN111032685A (zh) 2017-08-17 2020-04-17 诺沃挪第克公司 新型酰化胰岛素类似物及其用途
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR102646845B1 (ko) 2018-08-08 2024-03-14 주식회사 대웅제약 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
JP7439062B2 (ja) 2018-09-19 2024-02-27 ノヴォ・ノルディスク・リサーチ・センター・オックスフォード・リミテッド グルコース感受性インスリンおよびその使用
CN112839681A (zh) 2018-10-10 2021-05-25 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物及其医学用途
SG11202106167XA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin conjugates
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
KR20220112817A (ko) 2019-12-10 2022-08-11 사노피 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법
AU2021273262A1 (en) 2020-05-15 2022-12-08 Eli Lilly And Company Extended time action acylated insulin compounds
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof
CN115716877B (zh) * 2022-07-04 2023-09-01 北京惠之衡生物科技有限公司 一种表达glp-1和胰岛素缀合物多肽的重组工程菌
WO2024194897A1 (en) * 2023-03-22 2024-09-26 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) A glycation resistant insulin polypeptide and a method of preparing the same thereof

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832685A (en) 1952-05-24 1958-04-29 Crest Foods Co Inc Solubilization of milk proteins
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3719655A (en) 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033941A (en) 1975-12-17 1977-07-05 Eli Lilly And Company Process for purifying glucagon
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DK257988D0 (da) * 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
KR900701842A (ko) 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
AU631868B2 (en) 1989-04-20 1992-12-10 Mount Sinai School Of Medicine Of The City University Of New York, The Hepatospecific insulin analogues
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
AU628674B2 (en) 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
US5179189A (en) 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
DK45590D0 (da) 1990-02-21 1990-02-21 Novo Nordisk As
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK158390D0 (da) 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
WO1992001476A1 (en) 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
WO1998017320A1 (en) 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
TW224471B (da) 1991-11-26 1994-06-01 Lilly Co Eli
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
CZ287945B6 (cs) 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
GB9323588D0 (en) 1993-11-16 1994-01-05 Cortecs Ltd Hydrophobic preparation
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
NZ281112A (en) 1994-03-07 1998-04-27 Inhale Therapeutic Syst Powdered insulin delivered as an aerosol
US5639642A (en) 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
PL183698B1 (pl) 1995-03-17 2002-06-28 Novo Nordisk As Pochodna insuliny, kompozycja farmaceutyczna i zastosowanie pochodnej insuliny
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US20030104981A1 (en) 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
AU3255397A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
ATE278711T1 (de) 1996-07-11 2004-10-15 Novo Nordisk As Verfahren zur selektiven acetylierung
DK0821006T3 (da) 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
JP2001527387A (ja) 1997-01-24 2001-12-25 ノボ ノルディスク アクティーゼルスカブ 合成リーダーペプチド配列
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
CN1240718C (zh) 1997-10-24 2006-02-08 诺沃挪第克公司 人胰岛素衍生物的聚集体
EA200000453A1 (ru) 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CA2309955A1 (en) 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1086130A1 (en) 1998-06-12 2001-03-28 Kings College London Insulin analogue
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
AU758351B2 (en) 1998-08-25 2003-03-20 Alkermes, Inc. Stable spray-dried protein formulations
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7030083B2 (en) 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
ES2177323T3 (es) 1998-10-16 2002-12-01 Novo Nordisk As Preparaciones de insulina concentradas estables para la administracionpor via pulmonar.
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
ES2180511T3 (es) 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
WO2000061178A1 (en) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
AU4450700A (en) 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
WO2000069901A2 (en) 1999-05-19 2000-11-23 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
US6746853B1 (en) * 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CN1141974C (zh) 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
JP2004535401A (ja) 2001-05-21 2004-11-25 ネクター セラピューティックス 化学的に改変されたインスリンの肺投与
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
ES2333781T3 (es) 2001-09-07 2010-03-01 Biocon Limited Procedimientos de sintesis de conjugados de polipeptido insulina-oligomero y conjugados de polipeptido proinsulina-oligomero, y procedimientos de sintesis de los mismos.
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
EP1460992B1 (en) 2001-12-03 2009-03-11 Dor Biopharma, Inc. Stabilized reverse micelle compositions and uses thereof
AU2002314790A1 (en) 2001-12-05 2003-06-23 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
PL374949A1 (en) 2001-12-20 2005-11-14 Eli Lilly And Company Insulin molecule having protracted time action
EP1506003A1 (en) 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
JP5599543B2 (ja) 2002-05-07 2014-10-01 ノヴォ ノルディスク アー／エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN1165549C (zh) 2002-06-15 2004-09-08 江苏万邦生化医药股份有限公司 胰岛素的纯化方法
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
DE602004021603D1 (de) 2003-07-25 2009-07-30 Conjuchem Biotechnologies Inc Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
KR101152470B1 (ko) 2003-08-13 2012-06-01 바이오콘 리미티드 치료제용 마이크로-입자 지방산 염 고형 투약 제형
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
DE10358387A1 (de) 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
MXPA06012980A (es) 2004-05-10 2007-06-12 Nastech Pharm Co Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN101102789B (zh) * 2004-12-03 2012-05-30 罗得岛医院 阿尔茨海默病的诊断和治疗
EP1843790A2 (en) 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
EP1846447B1 (en) 2005-02-02 2013-08-21 Novo Nordisk A/S Insulin derivatives
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
WO2007006320A1 (en) 2005-07-12 2007-01-18 Sherine Hassan Abbas Helmy Drinkable oral insulin liquid and capsules
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
JP2009512709A (ja) 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
EP1991576B1 (en) 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
DK2074141T3 (da) 2006-09-22 2016-11-28 Novo Nordisk As Proteaseresistente insulinanaloger.
WO2008132229A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
AU2008257505B2 (en) 2007-06-01 2013-05-16 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
EP2017288A1 (en) 2007-07-16 2009-01-21 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
WO2009010428A1 (en) 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
KR20100053561A (ko) 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物

Also Published As

Publication number Publication date
HUE029512T2 (en) 2017-03-28
KR20150031494A (ko) 2015-03-24
AU2007298919C1 (en) 2014-02-06
CA2663074A1 (en) 2008-03-27
BRPI0717098A2 (pt) 2013-10-08
IL197609A0 (en) 2011-08-01
JP5864834B2 (ja) 2016-02-17
ES2601839T3 (es) 2017-02-16
MX2009002999A (es) 2009-04-01
EP2074141A1 (en) 2009-07-01
ZA200901838B (en) 2010-02-24
NO20091563L (no) 2009-04-20
KR101729986B1 (ko) 2017-04-25
CN101541830A (zh) 2009-09-23
TW200829600A (en) 2008-07-16
BRPI0717098B8 (pt) 2021-05-25
EP2074141B1 (en) 2016-08-10
AU2007298919A1 (en) 2008-03-27
JP2014129355A (ja) 2014-07-10
JP2010504087A (ja) 2010-02-12
PT2074141T (pt) 2016-11-10
US20100009898A1 (en) 2010-01-14
PL2074141T3 (pl) 2017-02-28
EP2404934A1 (en) 2012-01-11
IL197609A (en) 2017-04-30
US9018161B2 (en) 2015-04-28
BRPI0717098B1 (pt) 2018-08-07
RU2524150C2 (ru) 2014-07-27
KR20090071561A (ko) 2009-07-01
RU2009114324A (ru) 2010-10-27
WO2008034881A1 (en) 2008-03-27
KR101699370B1 (ko) 2017-02-14

Similar Documents

Publication Publication Date Title
DK2074141T3 (da) Proteaseresistente insulinanaloger.
AU2007298919B2 (en) Protease resistant insulin analogues
EP2254905B1 (en) Protease-stabilized insulin analogues
RU2571857C2 (ru) Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
AU710818B2 (en) Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP5695909B2 (ja) 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
WO2009133099A2 (en) Insulin precursors for diabetes treatment
US20110152183A1 (en) Derivatised hybrid peptides of amylin and salmon calcitonin